DodsonWE, KaminM, KrautL, OlsonWH, WuS-C. Topiramate titration to response: analysis of individualized therapy study (TRAITS). Ann Pharmacother2003; 37: 615–20.
2.
La PumaJ, SeltzerJ. Phase IV market steams ahead. Center Watch2002; 9(10):1–13.
3.
PriviteraM, FinchamR, PenryJ, ReifeR, KramerL, PledgerG, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology.1996; 46:1678–83.
4.
FaughtE, WilderBJ, RamsayRE, ReifeR, KramerLD, PledgerGW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YE Study Group. Neurology.1996; 46:1684–90.
5.
BitonV, EdwardsKR, MontourisGD, SackellaresJC, HardenCL, KaminM, et al. Topiramate titration and tolerability. Ann Pharmacother.2001; 35:173–9.
6.
PriviteraM, BrodieM, MattsonR, ChadwickD, NetoW, WangS, et al. Topiramate, carbamazepine and valproate monotherapy: a double-blind comparison in the spectrum of newly diagnosed epilepsy. Acta Neurol Scand, 2003; 107:165–75.
7.
AldenkampAP, BakerG, MulderOG, ChadwickD, CooperP, DoelmanJ, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia, 2000; 41:1167–78.
8.
FrenchJA. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials. Epilepsia, 2002; 43:951–5.
